

# Perimeter Medical Imaging AI Hosts Two Poster Presentations at the College of American Pathologists 2022 Annual Meeting

*Research provides validation of wide-field Optical Coherence Tomography (OCT) for microstructural analysis of tissue from multiple organs and tissue types*

TORONTO & DALLAS--(BUSINESS WIRE)-- Perimeter Medical Imaging AI, Inc. (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) – a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs – announced two poster presentations at the Annual Meeting of the College of American Pathologists 2022 (CAP22), which took place October 8 to 11, 2022 in New Orleans, LA. The research presented validates the potential use of Perimeter S-Series OCT to intraoperatively image specimens across a variety of tissue types, such as breast, thyroid, kidney, liver, lung, colon, heart, pancreas, spleen, and adrenal glands:

- Validation of Wide-Field Optical Coherence Tomography for Microstructural Analysis of Tissue From Multiple Organs ([Poster No. 108](#))
- Intraoperative Use of Wide-Field Optical Coherence Tomography to Evaluate Tissue Microstructure in the Oral Cavity and Oropharynx ([Poster No. 170](#))

Andrew Berkeley, Perimeter's Co-founder stated, "We were excited to present to leading pathologists at CAP22 with data that support the potential use of Perimeter's OCT medical imaging technology across several tissue types, including the analysis of margins in head and neck surgery. This research helps demonstrate that Perimeter S-Series has the potential to be used in a variety of settings to help 'bridge the gap' between the surgeon's need for immediate 'real time' info in the operating room with images that correlate to histological results, with a process that does not interfere with surgical procedures or final pathology."

## About Perimeter Medical Imaging AI, Inc.

Based in Toronto, Canada and Dallas, Texas, [Perimeter Medical Imaging AI](#) (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level, with 10x greater image resolution than X-ray and ultrasound, and 100x greater than MRI. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US\$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker

symbol “PINK” is a reference to the pink ribbons displayed during Breast Cancer Awareness Month.

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

## **Forward-Looking Statements**

This news release contains statements that constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. In this news release, words such as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management’s future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter ImgAssist; Perimeter’s expected development activities and the expected details regarding Perimeter’s ongoing clinical trials are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter’s control. Such forward-looking statements reflect Perimeter’s current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter’s financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter’s Management Discussion and Analysis for the year ended December 31, 2021, which is available on Perimeter’s SEDAR profile at [www.sedar.com](http://www.sedar.com), and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20221012006049/en/>

Chris Scott  
Chief Financial Officer  
Perimeter Medical Imaging AI, Inc.  
Investors: [investors@perimetermed.com](mailto:investors@perimetermed.com)

Toll-free: 888-988-7465 (PINK)

Jodi Regts  
Corporate Communications  
Perimeter Medical Imaging AI, Inc.  
Media: [media@perimetermed.com](mailto:media@perimetermed.com)  
Mobile: 469-743-1834

Source: Perimeter Medical Imaging AI, Inc.